https://www.selleckchem.com/pr....oducts/abr-238901.ht
Treatment with immune-checkpoint inhibitors in melanoma patients can cause immune-related adverse effects, such as vitiligo. In vitiligo, specific autoimmunity against melanocytes results in depigmentations of the skin. Melanoma-associated vitiligo occurring in melanoma patients treated with immune-checkpoint inhibitors can be seen as a good prognostic sign as higher survival rates in melanoma-associated vitiligo cases have been reported.Areas covered This review gives an insight in the pathophysiology, clinical presentation and mana
پسند
تبصرہ
بانٹیں
